2017

14/12/2017

Proteomics and Dimerix partner to improve the treatment of kidney disease

04/12/2017

Proteomics joins major health study to target lung disease

28/11/2017

Results of Meeting

28/11/2017

Proteomics AGM Presentation

27/11/2017

PromarkerD predictive diagnostic test to launch in Q1 2018

22/11/2017

Proteomics strengthens Board and Business Development team

03/11/2017

Appendix 3B – Issue of Employee Options

27/10/2017

Notice of Annual General Meeting

26/10/2017

Proteomics partnered consortium to receive $2 million

25/10/2017

Appendix 4C – September 2017 Quarterly Report

10/10/2017

Proteomics receives R&D tax incentive

14/09/2017

Change of Director’s Interest Notice

06/09/2017

PromarkerD predictive test results published – Diabetes Care

31/08/2017

Annual Report to shareholders

31/08/2017

Corporate Governance Statement and Appendix 4G

31/08/2017

Preliminary Final Report

22/08/2017

Appendix 3B

17/08/2017

Results of Extraordinary General Meeting

16/08/2017

US PromarkerD patent expanded to all kidney disease

17/07/2017

Appendix 3B

14/07/2017

Proteomics wins major analytical services contract

13/07/2017

Notice of Extraordinary General Meeting/Proxy Form

13/07/2017

Letter to Shareholders

13/06/2017

Clinical validation study confirms PromarkerD performance

09/05/2017

World leading laboratory launches clinical trials testing

27/04/2017

Appendix 4C – March 2017 Quarterly Report

18/04/2017

Appendix 3B

12/04/2017

Update on voluntary escrow and ASIC relief

11/04/2017

Research Report and Investor Briefing

04/04/2017

PromarkerD update

31/03/2017

Release from mandatory escrow and proposed voluntary escrow

27/03/2017

Frost & Sullivan- PromarkerD diagnostic test world leading

21/03/2017

Proteomics targets diabetic kidney disease in Asia

21/03/2017

Proteomics presents at Asia Biotech Invest 2017

08/02/2017

Diabetic kidney disease diagnostic test data published

13/01/2017

Appendix 3Y

04/01/2017

Change in Substantial Holding

03/01/2017

Change in Substantial Holding

Subscribe
  • This field is for validation purposes and should be left unchanged.